Structure-based discovery of glycomimetic FmlH ligands as inhibitors of bacterial adhesion during urinary tract infection

Proceedings of the National Academy of Sciences of the United States of America

Volumn 115, Issue 12, 2018, Pages E2819-E2828

  Kalas, Vasilios ^a   Hibbing, Michael E ^a   Maddirala, Amarendar Reddy ^a   Chugani, Ryan ^a   Pinkner, Jerome S ^a   Mydock McGrane, Laurel K ^a   Conover, Matt S ^a   Janetka, James W ^a   Hultgren, Scott J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic sparing therapeutic; Glycomimetics; Host pathogen interactions; Structure based drug design; Urinary tract infection

Indexed keywords

29 N ACETYL BETA GALACTOSAMINOSIDE; 4 Z 269; ADHESIN; ADHESIN FMIH; ANTIINFECTIVE AGENT; ARYL GALACTOSIDE; CARBOHYDRATE; GALACTOSIDE; LECTIN; MANNOSIDE; UNCLASSIFIED DRUG; URINARY TRACT AGENT; LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; BLADDER; CONTROLLED STUDY; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; HYDROGEN BOND; KIDNEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; URINARY TRACT INFECTION; X RAY CRYSTALLOGRAPHY; ANIMAL; C3H MOUSE; CHEMISTRY; DRUG EFFECT; ESCHERICHIA COLI INFECTION; METABOLISM; MICROBIOLOGY; MOLECULAR DOCKING; MOLECULAR MIMICRY; PATHOGENICITY; PRECLINICAL STUDY; PROCEDURES; SYNTHESIS; UROPATHOGENIC ESCHERICHIA COLI;

ADHESINS, ESCHERICHIA COLI; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL ADHESION; CRYSTALLOGRAPHY, X-RAY; DRUG EVALUATION, PRECLINICAL; ESCHERICHIA COLI INFECTIONS; FEMALE; GALACTOSIDES; HUMANS; KIDNEY; LIGANDS; MICE, INBRED C3H; MOLECULAR DOCKING SIMULATION; MOLECULAR MIMICRY; URINARY TRACT INFECTIONS; UROPATHOGENIC ESCHERICHIA COLI;

EID: 85044296757     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1720140115     Document Type: Article

References (58)

1. Foxman B (2003) Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs. Dis Mon 49:53-70.
2. Griebling TL (2005) Urologic diseases in America project: Trends in resource use for urinary tract infections in women. J Urol 173:1281-1287.
3. Gupta K, Hooton TM, Roberts PL, Stamm WE (2001) Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women. Ann Intern Med 135:9-16.
4. Foxman B (2010) The epidemiology of urinary tract infection. Nat Rev Urol 7:653-660.
5. Ramakrishnan K, Scheid DC (2005) Diagnosis and management of acute pyelonephritis in adults. Am Fam Physician 71:933-942.
6. Pertel PE, Haverstock D (2006) Risk factors for a poor outcome after therapy for acute pyelonephritis. BJU Int 98:141-147.
7. Efstathiou SP, et al. (2003) Acute pyelonephritis in adults: Prediction of mortality and failure of treatment. Arch Intern Med 163:1206-1212.
8. Roberts FJ, Geere IW, Coldman A (1991) A three-year study of positive blood cultures, with emphasis on prognosis. Rev Infect Dis 13:34-46.
9. WHO (2014) Antimicrobial resistance: Global report on surveillance 2014 (WHO, Geneva).
10. Guneysel O, Onur O, Erdede M, Denizbasi A (2009) Trimethoprim/sulfamethoxazole resistance in urinary tract infections. J Emerg Med 36:338-341.
11. Raz R, et al.; Israeli Urinary Tract Infection Group (2002) Empiric use of trimethoprimsulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis 34:1165-1169.
12. Aypak C, Altunsoy A, Düzgün N (2009) Empiric antibiotic therapy in acute uncomplicated urinary tract infections and fluoroquinolone resistance: A prospective observational study. Ann Clin Microbiol Antimicrob 8:27.
13. Kallen AJ, Welch HG, Sirovich BE (2006) Current antibiotic therapy for isolated urinary tract infections in women. Arch Intern Med 166:635-639.
14. Karlowsky JA, Hoban DJ, Decorby MR, Laing NM, Zhanel GG (2006) Fluoroquinoloneresistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: Results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study. Antimicrob Agents Chemother 50:2251-2254.
15. McGann P, et al. (2016) Escherichia coli harboring mcr-1 and blaCTX-M on a novel IncF plasmid: First report of mcr-1 in the United States. Antimicrob Agents Chemother 60: 4420-4421.
16. Rasko DA, Sperandio V (2010) Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov 9:117-128.
17. Ronald A (2003) The etiology of urinary tract infection: Traditional and emerging pathogens. Dis Mon 49:71-82.
18. Ronald AR, et al. (2001) Urinary tract infection in adults: Research priorities and strategies. Int J Antimicrob Agents 17:343-348.
19. Schreiber HL, 4th, et al. (2017) Bacterial virulence phenotypes of Escherichia coli and host susceptibility determine risk for urinary tract infections. Sci Transl Med 9: eaaf1283.
20. Waksman G, Hultgren SJ (2009) Structural biology of the chaperone-usher pathway of pilus biogenesis. Nat Rev Microbiol 7:765-774.
21. Wurpel DJ, Beatson SA, Totsika M, Petty NK, Schembri MA (2013) Chaperone-usher fimbriae of Escherichia coli. PLoS One 8:e52835.
22. Jones CH, et al. (1995) FimH adhesin of type 1 pili is assembled into a fibrillar tip structure in the Enterobacteriaceae. Proc Natl Acad Sci USA 92:2081-2085.
23. Mulvey MA, et al. (1998) Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science 282:1494-1497.
24. Mydock-McGrane LK, Hannan TJ, Janetka JW (2017) Rational design strategies for FimH antagonists: New drugs on the horizon for urinary tract infection and Crohn's disease. Expert Opin Drug Discov 12:711-731.
25. Jarvis C, et al. (2016) Antivirulence isoquinolone mannosides: Optimization of the biaryl aglycone for FimH lectin binding affinity and efficacy in the treatment of chronic UTI. ChemMedChem 11:367-373.
26. Mydock-McGrane L, et al. (2016) Antivirulence C-mannosides as antibiotic-sparing, oral therapeutics for urinary tract infections. J Med Chem 59:9390-9408.
27. Han Z, et al. (2010) Structure-based drug design and optimization of mannoside bacterial FimH antagonists. J Med Chem 53:4779-4792.
28. Cusumano CK, et al. (2011) Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci Transl Med 3:109ra115.
29. Grabosch C, Hartmann M, Schmidt-Lassen J, Lindhorst TK (2011) Squaric acid monoamide mannosides as ligands for the bacterial lectin FimH: Covalent inhibition or not? ChemBioChem 12:1066-1074.
30. Kleeb S, et al. (2015) FimH antagonists: Bioisosteres to improve the in vitro and in vivo PK/PD profile. J Med Chem 58:2221-2239.
31. Chalopin T, et al. (2016) Second generation of thiazolylmannosides, FimH antagonists for E. coli-induced Crohn's disease. Org Biomol Chem 14:3913-3925.
32. Mydock-McGrane LK, Cusumano ZT, Janetka JW (2016) Mannose-derived FimH antagonists: A promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease. Expert Opin Ther Pat 26:175-197.
33. Wurpel DJ, et al. (2014) F9 fimbriae of uropathogenic Escherichia coli are expressed at low temperature and recognise Galβ1-3GlcNAc-containing glycans. PLoS One 9: e93177.
34. Conover MS, et al. (2016) Inflammation-induced adhesin-receptor interaction provides a fitness advantage to uropathogenic E. coli during chronic infection. Cell Host Microbe 20:482-492.
35. Kalas V, et al. (2017) Evolutionary fine-tuning of conformational ensembles in FimH during host-pathogen interactions. Sci Adv 3:e1601944.
36. Le Trong I, et al. (2010) Structural basis for mechanical force regulation of the adhesin FimH via finger trap-like beta sheet twisting. Cell 141:645-655.
37. Sauer MM, et al. (2016) Catch-bond mechanism of the bacterial adhesin FimH. Nat Commun 7:10738.
38. Mayer K, et al. (2017) Urinary tract infection: Which conformation of the bacterial lectin FimH is therapeutically relevant? J Med Chem 60:5646-5662.
39. Hannan TJ, Mysorekar IU, Hung CS, Isaacson-Schmid ML, Hultgren SJ (2010) Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog 6:e1001042.
40. Murawski IJ, et al. (2010) The C3H/HeJ inbred mouse is a model of vesico-ureteric reflux with a susceptibility locus on chromosome 12. Kidney Int 78:269-278.
41. Subashchandrabose S, et al. (2014) Host-specific induction of Escherichia coli fitness genes during human urinary tract infection. Proc Natl Acad Sci USA 111:18327-18332.
42. Bouckaert J, et al. (2006) The affinity of the FimH fimbrial adhesin is receptor-driven and quasi-independent of Escherichia coli pathotypes. Mol Microbiol 61:1556-1568.
43. Hung CS, et al. (2002) Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection. Mol Microbiol 44:903-915.
44. Ernst B, Magnani JL (2009) From carbohydrate leads to glycomimetic drugs. Nat Rev Drug Discov 8:661-677.
45. Hsu CH, et al. (2016) The dependence of carbohydrate-aromatic interaction strengths on the structure of the carbohydrate. J Am Chem Soc 138:7636-7648.
46. Hudson KL, et al. (2015) Carbohydrate-aromatic interactions in proteins. J Am Chem Soc 137:15152-15160.
47. Ter Kuile BH, Kraupner N, Brul S (2016) The risk of low concentrations of antibiotics in agriculture for resistance in human health care. FEMS Microbiol Lett 363:fnw210.
48. Llor C, Bjerrum L (2014) Antimicrobial resistance: Risk associated with antibiotic overuse and initiatives to reduce the problem. Ther Adv Drug Saf 5:229-241.
49. Kardas P, Devine S, Golembesky A, Roberts C (2005) A systematic review and metaanalysis of misuse of antibiotic therapies in the community. Int J Antimicrob Agents 26:106-113.
50. Chang Q, Wang W, Regev-Yochay G, Lipsitch M, Hanage WP (2015) Antibiotics in agriculture and the risk to human health: How worried should we be? Evol Appl 8: 240-247.
51. Pinkner JS, et al. (2006) Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc Natl Acad Sci USA 103:17897-17902.
52. Trott O, Olson AJ (2010) AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455-461.
53. Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG (2012) ZINC: A free tool to discover chemistry for biology. J Chem Inf Model 52:1757-1768.
54. O'Boyle NM, et al. (2011) Open Babel: An open chemical toolbox. J Cheminform 3:33.
55. Battye TG, Kontogiannis L, Johnson O, Powell HR, Leslie AG (2011) iMOSFLM: A new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr D Biol Crystallogr 67:271-281.
56. Kabsch W (2010) Xds. Acta Crystallogr D Biol Crystallogr 66:125-132.
57. Winn MD, et al. (2011) Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67:235-242.
58. Adams PD, et al. (2010) PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66:213-221.